Challenges and opportunities for improving pre... - CLL Support
Challenges and opportunities for improving precision medicine in CLL outlined in a new review article
You need to be a member of this community to see this post.
11 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Review article summarises management strategies for those with CLL harbouring complex karyotype
On 6 January 2025, the journal BJ Haem published a review article titled Management...
Improving Treatment Options for Patients with Double Refractory CLL - patients who progressed after treatment with both cBTKis and BCL2i
Abstract
The proliferation and survival of chronic lymphocytic leukemia...
Chronic lymphocytic leukemia treatment algorithm 2022
This 29 November 2022 review article published in the Blood Cancer Journal presents an...
Consensus recommendations for CLL/SLL treatment selection and sequencing in the US
In the past ten years, there has been a shift away from treating CLL/SLL with chemoimmunotherapy to...
CLLSA and Leukaemia Care Joint Response to NHS England regarding Ibrutinib Prescribing as per NICE TA
This is the letter sent to Professor Peter Clarke on 2nd July 2018 for the review of Ibrutinib...
Related Posts
- Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis
- Ibrutinib-Venetoclax is the recommended first-line therapy for fit Arab patients with CLL in the Gulf region
- Venetoclax has been added to the Pharmaceutical Benefits Scheme in Australia for use as a retreatment for CLL/SLL
- Median PFS for FCR treated CLL patients with IGHV-M was 14.6 years vs 4.2 years for patients with IGHV-UM. V+O and I+R look to be superior
- Efficacy and safety of new‑generation BTKis (primarily acalabrutinib and zanubrutinib) in CLL/SLL: a systematic review and meta‑analysis
